On May 10, 2023 Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, reported that research involving its SNAP-CAR technology was detailed in a peer-reviewed article published in the peer-reviewed journal, Nature Communications (Press release, Coeptis Pharmaceuticals, MAY 10, 2023, View Source [SID1234631413]). SNAP-CAR is a multi-antigen chimeric antigen receptor T cell (CAR T) technology that can be adapted to different cancer indications, including hematologic and solid tumors.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The article titled, "Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting," describes key advances in antigen receptor design to develop "universal" receptor systems for diverse programming of cell behaviors using covalent chemistry. Using in vitro and in vivo models, the authors demonstrated that the SNAP-CAR platform provides a powerful adaptor strategy for fully programmable targeting of engineered cells to multiple antigens. Further, it was concluded that these systems have the potential for clinical application and biotechnological utility by providing researchers with the ability to rapidly screen CAR and synNotch antibody candidates and to rewire and activate cellular programs in response to highly specific antibody-antigen interactions.
"This research highlights key advances in antigen receptor design, including the creation of a universal adaptor synNotch system and a universal CAR system that act through self-labeling enzyme chemistry, representing a potential breakthrough in programmable antigen targeting," said Jason Lohmueller, Ph.D., Assistant Professor of Surgery and Immunology in the Division of Surgical Oncology Research, University of Pittsburgh. "These ‘universal’ receptor systems, for which receptor specificity can be directed post-translationally via covalent attachment of a co-administered antibody, offer the potential to allow for one population of T cells to target multiple tumor antigens, enabling the development of cell therapies for a wide range of cancers, including hematologic and solid tumors."
"SNAP-CAR represents a powerful technology with the potential to be engineered to address numerous cancers, including HER2-expressing cancer, which we are targeting as our potential first-in-human clinical development program," said Dave Mehalick, President and CEO of Coeptis Therapeutics. "Having research on SNAP-CAR published in such a prestigious scientific journal as Nature Communications provides further validation of the technology’s potential and the groundbreaking work being conducted by Dr. Lohmueller and his team at the University of Pittsburgh."
About SNAP-CAR
SNAP-CAR, which Coeptis Therapeutics licensed from the University of Pittsburgh, is designed to be a "universal" CAR T cell therapy platform that can be adapted to different cancer indications. Instead of directly binding to a target on the tumor cell, CAR T cells are co-administered with one or more antibody adaptors that bind to the tumor cells and are fitted with a chemical group that irreversibly connects them to the SNAP-CAR on the therapeutic cells via a covalent bond. Pre-clinical studies in mice have demonstrated that by targeting tumors via antibody adaptor molecules, the SNAP-CAR therapy provides a highly programmable therapeutic platform.